Stephen J Fuller1, Sally A Osborne1, Sam J Leonard1, Michelle A Hardyman1, George Vaniotis2, Bruce G Allen3, Peter H Sugden1, Angela Clerk4. 1. School of Biological Sciences, University of Reading, Whiteknights Campus, Reading, Berkshire RG6 6AS, UK. 2. Institut de Cardiologie de Montréal Centre de Recherche, Montréal, QC, Canada H1T 1C8 Département de Biochimie, Université de Montréal, Montréal, QC, Canada H3T 1J4. 3. Institut de Cardiologie de Montréal Centre de Recherche, Montréal, QC, Canada H1T 1C8 Département de Biochimie, Université de Montréal, Montréal, QC, Canada H3T 1J4 Département de Médecine, Université de Montréal, Montréal, QC, Canada H3T 1J4. 4. School of Biological Sciences, University of Reading, Whiteknights Campus, Reading, Berkshire RG6 6AS, UK a.clerk@reading.ac.uk.
Abstract
AIMS: Protein kinases are potential therapeutic targets for heart failure, but most studies of cardiac protein kinases derive from other systems, an approach that fails to account for specific kinases expressed in the heart and the contractile cardiomyocytes. We aimed to define the cardiomyocyte kinome (i.e. the protein kinases expressed in cardiomyocytes) and identify kinases with altered expression in human failing hearts. METHODS AND RESULTS: Expression profiling (Affymetrix microarrays) detected >400 protein kinase mRNAs in rat neonatal ventricular myocytes (NVMs) and/or adult ventricular myocytes (AVMs), 32 and 93 of which were significantly up-regulated or down-regulated (greater than two-fold), respectively, in AVMs. Data for AGC family members were validated by qPCR. Proteomics analysis identified >180 cardiomyocyte protein kinases, with high relative expression of mitogen-activated protein kinase cascades and other known cardiomyocyte kinases (e.g. CAMKs, cAMP-dependent protein kinase). Other kinases are poorly investigated (e.g. Slk, Stk24, Oxsr1). Expression of Akt1/2/3, BRaf, ERK1/2, Map2k1, Map3k8, Map4k4, MST1/3, p38-MAPK, PKCδ, Pkn2, Ripk1/2, Tnni3k, and Zak was confirmed by immunoblotting. Relative to total protein, Map3k8 and Tnni3k were up-regulated in AVMs vs. NVMs. Microarray data for human hearts demonstrated variation in kinome expression that may influence responses to kinase inhibitor therapies. Furthermore, some kinases were up-regulated (e.g. NRK, JAK2, STK38L) or down-regulated (e.g. MAP2K1, IRAK1, STK40) in human failing hearts. CONCLUSION: This characterization of the spectrum of kinases expressed in cardiomyocytes and the heart (cardiomyocyte and cardiac kinomes) identified novel kinases, some of which are differentially expressed in failing human hearts and could serve as potential therapeutic targets. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Protein kinases are potential therapeutic targets for heart failure, but most studies of cardiac protein kinases derive from other systems, an approach that fails to account for specific kinases expressed in the heart and the contractile cardiomyocytes. We aimed to define the cardiomyocyte kinome (i.e. the protein kinases expressed in cardiomyocytes) and identify kinases with altered expression in human failing hearts. METHODS AND RESULTS: Expression profiling (Affymetrix microarrays) detected >400 protein kinase mRNAs in rat neonatal ventricular myocytes (NVMs) and/or adult ventricular myocytes (AVMs), 32 and 93 of which were significantly up-regulated or down-regulated (greater than two-fold), respectively, in AVMs. Data for AGC family members were validated by qPCR. Proteomics analysis identified >180 cardiomyocyte protein kinases, with high relative expression of mitogen-activated protein kinase cascades and other known cardiomyocyte kinases (e.g. CAMKs, cAMP-dependent protein kinase). Other kinases are poorly investigated (e.g. Slk, Stk24, Oxsr1). Expression of Akt1/2/3, BRaf, ERK1/2, Map2k1, Map3k8, Map4k4, MST1/3, p38-MAPK, PKCδ, Pkn2, Ripk1/2, Tnni3k, and Zak was confirmed by immunoblotting. Relative to total protein, Map3k8 and Tnni3k were up-regulated in AVMs vs. NVMs. Microarray data for human hearts demonstrated variation in kinome expression that may influence responses to kinase inhibitor therapies. Furthermore, some kinases were up-regulated (e.g. NRK, JAK2, STK38L) or down-regulated (e.g. MAP2K1, IRAK1, STK40) in human failing hearts. CONCLUSION: This characterization of the spectrum of kinases expressed in cardiomyocytes and the heart (cardiomyocyte and cardiac kinomes) identified novel kinases, some of which are differentially expressed in failing human hearts and could serve as potential therapeutic targets. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Chunguang Wang; Juuso H Taskinen; Heli Segersvärd; Katariina Immonen; Riikka Kosonen; Johanna M Tolva; Mikko I Mäyränpää; Petri T Kovanen; Vesa M Olkkonen; Juha Sinisalo; Mika Laine; Ilkka Tikkanen; Päivi Lakkisto Journal: Front Cardiovasc Med Date: 2022-06-17
Authors: Marisa J Stachowski-Doll; Maria Papadaki; Thomas G Martin; Weikang Ma; Henry M Gong; Stephanie Shao; Shi Shen; Nitha Aima Muntu; Mohit Kumar; Edith Perez; Jody L Martin; Christine S Moravec; Sakthivel Sadayappan; Stuart G Campbell; Thomas Irving; Jonathan A Kirk Journal: Circ Res Date: 2022-02-16 Impact factor: 23.213
Authors: Sebastian Mathea; Kamal R Abdul Azeez; Eidarus Salah; Cynthia Tallant; Finn Wolfreys; Rebecca Konietzny; Roman Fischer; Hua Jane Lou; Paul E Brennan; Gisela Schnapp; Alexander Pautsch; Benedikt M Kessler; Benjamin E Turk; Stefan Knapp Journal: ACS Chem Biol Date: 2016-03-31 Impact factor: 5.100
Authors: Yuanjun Guo; Jennifer Y Sui; Kyungsoo Kim; Zhentao Zhang; Xiaoyan A Qu; Young-Jae Nam; Robert N Willette; Joey V Barnett; Bjorn C Knollmann; Thomas Force; Hind Lal Journal: Circulation Date: 2019-10-04 Impact factor: 29.690
Authors: Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu Journal: Circ Res Date: 2019-09-19 Impact factor: 17.367